Advanced Filters
noise

Semaglutide Clinical Trials

A listing of Semaglutide medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 66 clinical trials
K Katja Marie Leitner, MD

Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance

Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile. As the most commonly prescribed drug in this class, semaglutide is effective in both diabetic and non-diabetic individuals. However, treatment responses vary significantly, with non-diabetic individuals typically experiencing better weight loss …

18 - 60 years of age All Phase N/A
J Joji Suzuki, MD

Semaglutide for Helping Opioid Recovery

The is a pilot, 12-week, double-blind, placebo-controlled, randomized trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching placebo (n=23). The primary aim is to determine the effects of semaglutide on cue-reactivity among individuals with OUD. The secondary aim …

18 years of age All Phase 2
C Claus Z Simonsen, MD

Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke

Can Semaglutide help reduce the damage caused by a stroke? ASSET trial is a national, multicenter, clinical trial, investigating the safety and efficacy of Semaglutide in non-diabetic patients with acute ischemic stroke. Stroke is a worldwide leading cause of long-term disability and death. In the most common type of stroke …

18 years of age All Phase 2
H Honorary Clinical Assistant Professor

Effect of Semaglutide in Patients With Psoriasis and Obesity

Obesity is well known to be an important comorbidity of psoriasis. It gives rise to higher risk of psoriatic arthritis, more severe disease and also poorer response to biologics. Weight loss can lead to reduction in psoriasis severity. Previous studies had demonstrated the efficacy of older glucagon-like peptide-1 receptor agonist …

18 - 75 years of age All Phase 3
L Lukasz Szczerbinski, MD, PhD

Genetics of the Acute Response to Oral Semaglutide

The study aims to investigate the genetic basis of the response to short-term (3 months) orally administered semaglutide treatment, in terms of improving metabolic parameters, including the hormonal response to a standardized meal, and changes in body composition and liver steatosis. In the study, parameters such as fasting and 2-hour …

18 - 65 years of age All Phase N/A

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

18 - 75 years of age All Phase 2

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

18 years of age All Phase 3
M Mehdi Farokhnia, M.D., M.P.H.

Semaglutide Therapy for Alcohol Reduction (STAR)

Background Alcohol use disorder (AUD) is a problematic pattern of alcohol use accompanied by clinically significant medical consequences. Medications can help most people reduce their drinking, but the number is limited, and additional treatment options are needed. Objective To test if a medication named Semaglutide may reduce alcohol drinking in …

18 - 110 years of age All Phase 2
C Chytaine Hall

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

The recent introduction of the new generation of anti-obesity medications (AOMs) will change the future of obesity treatment. These highly effective medications, such as high-dose semaglutide and tirzepatide, are hormone analogues that augment the incretin function and exert multiple physiological effects by activating glucagon-like peptide-1 (GLP-1) and/or glucose-dependent insulinotropic polypeptide …

18 - 70 years of age All Phase 4
t tamer abdelaziz

Effect of Itopride on Semaglutide Gastroparesis

Semaglutide delays gastric emptying and increases the risk of aspiration with anesthesia; So, the addition of prokinetics as Itopride, could enhance gastric emptying and hasten surgery. The investigator will evaluate the effect of Itopride on Semaglutide-induced gastroparesis and residual gastric contents after 8 hours of fasting by gastric ultrasound before …

40 - 60 years of age Female Phase 4

Simplify language using AI